𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The molecular pharmacology of symplostatin 1: A new antimitotic dolastatin 10 analog

✍ Scribed by Susan L. Mooberry; Rachel M. Leal; Tina L. Tinley; Hendrik Luesch; Richard E. Moore; Thomas H. Corbett


Book ID
102269687
Publisher
John Wiley and Sons
Year
2003
Tongue
French
Weight
314 KB
Volume
104
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Symplostatin 1, an analog of dolastatin 10, was recently isolated from cyanobacteria of the genus Symploca. Symplostatin 1 is a potent inhibitor of cell proliferation with IC~50~ values in the low nanomolar range and it exhibits efficacy against a variety of cancer cell types. Symplostatin 1 caused the formation of abnormal mitotic spindles and accumulation of cells in metaphase at concentrations that had only minor effects on interphase microtubules. At higher concentrations, symplostatin 1 caused the loss of interphase microtubules. Cell cycle analysis revealed that symplostatin 1 caused G~2~/M arrest, consistent with its effects on mitotic spindles. Symplostatin 1 initiated the phosphorylation of Bcl‐2, formation of micronuclei and activation of caspase 3, indicating induction of apoptosis. The cellular effects of symplostatin 1 are consistent with other antimitotic tubulin‐targeting drugs. Tubulin polymerization experiments indicated that symplostatin 1 potently inhibits the assembly of purified tubulin, suggesting that tubulin may be its intracellular target. Some microtubule‐targeting agents are reported to have antiangiogenic activity and therefore the effects of symplostatin 1 on endothelial cell proliferation and invasion were evaluated. Symplostatin 1 was found to be a potent inhibitor of both endothelial cell proliferation and invasion. Because of its potent and broad activity in vitro, symplostatin 1 was evaluated in vivo. Symplostatin 1 was active against murine colon 38 and murine mammary 16/C; however, it was poorly tolerated and the mice were slow to recover from the toxicity. The data indicate that symplostatin 1 has a mechanism of action similar to dolastatin 10. © 2003 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


ANNOUNCEMENTS: 4th Annual Meeting of the
ANNOUNCEMENTS: 4th Annual Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT) The Marriott, Irvine, CA, USA 28–31 January 1999, Keystone Symposia Ocular Cell & Molecular Biology (OCMB) Announces Dean Bok, Ph.D. as the winner of the first OCMB Prize, Keystone OCMB Symposium, 1999 Keystone Colorado 5–10 February 1999, Call for Abstracts and Registration Organizers: Steven E. Wilson and Joe Hollyfield Registration and Abstract Forms available from: Keystone Symposia on Molecular and Cellular Biology Drawer 1630 Silverthorn, Colorado 80498 Telephone: 800-253-0685 Fax: 970-262-1525 E-mail: [email protected], XIV International Congress of Eye Research Santa Fe, New Mexico 15–20 October 2000, XV International Congress of Eye Research (2002) Proposals for the International Congress of Eye Research meeting to be held in the year 2002 are now being accepted by the ISER Council. The Jules François Prize of the Belgian Ophthalmological Societies 2000 The aim of the Jules François Prize is to encourage scientific research in ophthalmology. The prize of 10.000 U.S. Dollars will be awarded to a young scientist who has made an important contribution to ophthalmology. Eligibility: All topics in the field of fundamental and/or clinical research in ophthalmology will be considered. The application should be sent jointly with a curriculum vitae, the list of all publications and 3 copies of the candidates' 10 most relevant publications. The candidate should not be older than 40 years by 31 December 1999. Mailing Address: Jules François Foundation Secretary Prof. Dr. M. Hanssens Dienst Oogheelkunde De Pintelaan 185 B-9000 Gent, Belgium
📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 235 KB